Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.
about
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesManagement of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or ProctosigmoiditisAnti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats.Budesonide Use and Hospitalization Rate in Crohn's Disease: Results From a Cohort at a Tertiary Care IBD Referral Center.Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats.Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis.Update on the Medical Management of Crohn's Disease.Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.Excessive weight gain is associated with an increased risk for pouch failure in patients with restorative proctocolectomy.Inhibition of Rac family protein impairs colitis and colitis-associated cancer in mice.Degradation rates and products of fluticasone propionate in alkaline solutions.Amelioration of severe TNBS induced colitis by novel AP-1 and NF- κ B inhibitors in rats
P2860
Q27008246-EDF4C03C-E85D-4B3A-8570-6C31E8BE7C41Q33819473-416C308F-3341-419D-A6DA-5DB22266F874Q36210189-C03ECB82-BB83-434E-A300-80F13D36590CQ36901080-B6D59025-2B0B-4E89-9797-F65AC21E7BA3Q37233955-461E9BD6-C7ED-4CD8-B42D-E954B7D43D8BQ37697523-C51BCE11-61DF-4D97-9AAB-7F5E9CCC8A89Q37707732-1F096604-57BB-466A-974E-DC45E5527A3DQ37720153-8C6848E5-76DE-47A0-A543-7716B6E39A74Q38585634-29281FC0-C3CB-41DE-B027-8CCBA57EFCDEQ38622923-6E699A1B-185E-46B8-ACB7-CE6B6D413A88Q38659150-B879FA88-3669-4DA3-A2C2-DBD0854A2858Q38960072-2AF71178-4F80-48BE-B4BE-FDA573693677Q39251794-F1D15692-C4CB-4382-BC89-9FCA9375E6E5Q42409308-5940C9DD-9947-4A37-948C-7E8263212CF5Q42695145-56011399-6535-48BE-AD7A-6462F0F9EC64Q45963829-C395BA94-14D5-406C-A029-5995240E0291Q48507180-9C0054D5-6679-4EB7-9835-CFDEEB9F7E69Q49294663-8F73DC6F-63FD-43FB-8EA8-C01948E346A4Q59100894-6E22713E-4BEE-4F9B-9136-7FB3AC0465E9
P2860
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@ast
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@en
type
label
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@ast
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@en
prefLabel
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@ast
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@en
P2860
P356
P1476
Glucocorticosteroids in the tr ...... minimizing systemic activity.
@en
P2093
Cosimo Prantera
Stefano Marconi
P2860
P304
P356
10.1177/1756283X12473675
P577
2013-03-01T00:00:00Z